Hepatitis B virus reactivation in patients with psoriasis on biologic therapies: a retrospective study
S Özçelik, FA Kılı - Turkish Journal of Dermatology, 2020 - journals.lww.com
Background: There are limited data on the safety of biological therapies in psoriasis patients
with hepatitis B virus (HBV) infection in the literature, and are still ongoing controversies …
with hepatitis B virus (HBV) infection in the literature, and are still ongoing controversies …
[HTML][HTML] Risk of reactivation of hepatitis B virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM …
J Sanz-Bueno, F Vanaclocha, I García-Doval… - Actas Dermo …, 2015 - Elsevier
Introduction and objectives A 5% risk of reactivation of hepatitis B virus (HBV) infection has
been reported in patients with diseases other than psoriasis treated with tumor necrosis …
been reported in patients with diseases other than psoriasis treated with tumor necrosis …
Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature
Background Patients with psoriasis on biologic therapies and a history of viral hepatitis carry
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …
Evaluation of risk for hepatitis B virus reactivation in patients with psoriasis treated with biologic therapies: a single-center retrospective study
GH Tabak, N Akdoğan, SD Günaydın, YE Parlar… - Archives of …, 2024 - Springer
To the editor, Great efficacy and adequate compliance of biological therapy have made
biologics excellent alternatives in psoriasis. Hepatitis B virus (HBV) infection plays important …
biologics excellent alternatives in psoriasis. Hepatitis B virus (HBV) infection plays important …
Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study
HY Chiu, YM Chiu, NFC Liao, CC Chi, TF Tsai… - Journal of the American …, 2021 - Elsevier
Background The increasing use of biologics is accompanied by a risk of hepatitis B (HBV)
and C virus (HCV) reactivation. Objective To determine the predictors of HBV and HCV …
and C virus (HCV) reactivation. Objective To determine the predictors of HBV and HCV …
Risk for hepatitis b virus reactivation in patients with psoriasis treated with biological agents: A systematic review and meta-analysis
X Wang, M Zhang, Y Chen, Y Liu, Y Yu, X Huang… - Dermatology and …, 2022 - Springer
Introduction Notwithstanding their numerous advantages, biological treatments have many
limitations when treating patients with psoriasis (PsO) and hepatitis B (HB). Clinicians need …
limitations when treating patients with psoriasis (PsO) and hepatitis B (HB). Clinicians need …
Managing psoriasis in patients with HBV or HCV infection: practical considerations
S Piaserico, F Messina, FP Russo - American Journal of Clinical …, 2019 - Springer
Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …
Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management
MV Cannizzaro, C Franceschini… - … : Targets and Therapy, 2017 - Taylor & Francis
The risk of hepatitis B virus (HBV) reactivation (HBVr) in chronic HBV carriers, in occult HBV
patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis …
patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis …
Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysis
L Li, X Jiang, L Fu, L Zhang, Y Feng - Clinical and Experimental Medicine, 2023 - Springer
Some biological therapies for psoriasis can cause the reactivation of viral infections.
Although recent studies suggest no increased rate of reactivation with biological therapies …
Although recent studies suggest no increased rate of reactivation with biological therapies …
Use of anti‐tumor necrosis factor‐α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan
YT CHO, CH CHEN, HY CHIU… - The Journal of …, 2012 - Wiley Online Library
The use of anti‐tumor necrosis factor (TNF)‐α therapy in patients with psoriasis who are
hepatitis B virus (HBV) carriers is usually not recommended, and routine antiviral …
hepatitis B virus (HBV) carriers is usually not recommended, and routine antiviral …
相关搜索
- biologic therapies patients with psoriasis
- virus reactivation patients with psoriasis
- meta analysis patients with psoriasis
- biologic therapies virus reactivation
- virus reactivation risk for hepatitis
- biologic therapies risk for hepatitis
- viral hepatitis biologic agents
- reactivation rates hiv in patients
- risk for hepatitis patients with psoriasis
- hcv infection patients with hbv
- retrospective analysis risk of reactivation
- practical considerations patients with hbv
- psoriasis patients prevention and management
- psoriasis in patients biologic agents
- virus reactivation biologic agents
- psoriasis patients risk of reactivation